MRUS Merus BV

$95.76

*Only the 1D chart reflects 15-min delayed quotes during market hours. Other timeframes update after market close.

Reporting for fiscal period ending —
Expected on —
Report Time: Unknown Release Time
The Whisper Number
—
Consensus Estimate: —
Revenue Estimate: —

Latest Earnings Insight

Updated On 11/21/2025

About Merus BV

Merus NV, a clinical-stage immuno-oncology company, is dedicated to the discovery and development of bispecific antibody therapies in the Netherlands. The company is headquartered in Utrecht, the Netherlands.

Website: https://www.merus.nl

Sector
LIFE SCIENCES
Industry
PHARMACEUTICAL PREPARATIONS
Exchange
NASDAQ
Country
USA
Currency
USD
Fiscal Year End
December
CIK
1651311
Address
YALELAAN 62, 3584 CM UTRECHT, NL
Valuation
Market Cap
$2.97B
P/E Ratio
nan
PEG Ratio
0.00
Price to Book
4.59
Performance
EPS
$-3.35
Dividend Yield
—
Profit Margin
0.00%
ROE
-42.90%
Technicals
50D MA
$43.94
200D MA
$47.51
52W High
$61.61
52W Low
$33.19
Fundamentals
Shares Outstanding
69M
Target Price
$86.79
Beta
1.03

MRUS EPS Estimates vs Actual

● Estimated
● Actual

MRUS News & Sentiment

Oct 24, 2025 • GlobeNewswire NEUTRAL
Merus' Interim Data on Petosemtamab in Metastatic Colorectal Cancer Demonstrates Monotherapy Activity and Robust Response Rate in Combination with FOLFOX/FOLFIRI with Well Tolerated Safety
- 100% response rate in 1L left-sided mCRC ( n=8, confirmed and unconfirmed ...
Oct 14, 2025 • Benzinga NEUTRAL
Merus Announces Publication of an Abstract on Petosemtamab in Metastatic Colorectal Cancer at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics - Merus ( NASDAQ:MRUS )
- Petosemtamab in combination with FOLFOX /FOLFIRI ( 1L and 2L mCRC ) and as monotherapy ( 3L+ mCRC ) , demonstrates antitumor activity and a manageable safety profile
Oct 14, 2025 • GlobeNewswire NEUTRAL
Merus Announces Publication of an Abstract on Petosemtamab in Metastatic Colorectal Cancer at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
- Petosemtamab in combination with FOLFOX /FOLFIRI ( 1L and 2L mCRC ) and as monotherapy ( 3L+ mCRC ) , demonstrates antitumor activity and a manageable safety profile ...
Oct 13, 2025 • GlobeNewswire NEUTRAL
Merus Announces Petosemtamab in Metastatic Colorectal Cancer Abstract Selected for Plenary Session Oral Presentation at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
- Plenary session oral presentation: Friday, October 24 10:00 -11:40 a.m. ET ...
Sep 29, 2025 • GlobeNewswire SOMEWHAT-BULLISH
Genmab to Acquire Merus, Expanding Late-Stage Pipeline and Accelerating into a Wholly Owned Model
Company Announcement ...
Aug 06, 2025 • Benzinga NEUTRAL
Merus to Present at the Canaccord Genuity 45th Annual Growth Conference - Merus ( NASDAQ:MRUS )
UTRECHT, The Netherlands and CAMBRIDGE, Mass., Aug. 06, 2025 ( GLOBE NEWSWIRE ) -- Merus N.V.
Sentiment Snapshot

Average Sentiment Score:

0.103
50 articles with scored sentiment

Overall Sentiment:

Neutral

MRUS Reported Earnings

Aug 05, 2025
Jun 30, 2025 (Post market)
-1.09 Surprise
  • Reported EPS: $-2.23
  • Estimate: $-1.14
  • Whisper: —
  • Surprise %: -95.6%
May 07, 2025
Mar 31, 2025 (Pre market)
-0.34 Surprise
  • Reported EPS: $-1.40
  • Estimate: $-1.06
  • Whisper: —
  • Surprise %: -31.6%
Feb 27, 2025
Dec 31, 2024 (Pre market)
0.41 Surprise
  • Reported EPS: $-0.49
  • Estimate: $-0.90
  • Whisper: —
  • Surprise %: 45.7%
Oct 31, 2024
Sep 30, 2024 (Pre market)
-0.58 Surprise
  • Reported EPS: $-1.46
  • Estimate: $-0.88
  • Whisper: —
  • Surprise %: -65.9%
Aug 01, 2024
Jun 30, 2024 (Post market)
-0.05 Surprise
  • Reported EPS: $-0.81
  • Estimate: $-0.76
  • Whisper: —
  • Surprise %: -6.6%
May 08, 2024
Mar 31, 2024 (Post market)
0.22 Surprise
  • Reported EPS: $-0.59
  • Estimate: $-0.81
  • Whisper: —
  • Surprise %: 27.2%
Feb 28, 2024
Dec 31, 2023 (Post market)
-0.3 Surprise
  • Reported EPS: $-1.04
  • Estimate: $-0.74
  • Whisper: —
  • Surprise %: -40.5%
Nov 02, 2023
Sep 30, 2023 (Post market)
0.3 Surprise
  • Reported EPS: $-0.43
  • Estimate: $-0.73
  • Whisper: —
  • Surprise %: 41.1%
Aug 07, 2023
Jun 30, 2023 (Post market)
0.22 Surprise
  • Reported EPS: $-0.66
  • Estimate: $-0.88
  • Whisper: —
  • Surprise %: 25.0%

Financials